Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Hong Kong 2024-12-02 07:40
CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China 2024-11-30 09:00
BGM Group Ltd Pioneers Innovation in AI Technology, Fostering Holistic Integration of Healthcare and Insurtech 2024-11-29 23:58
MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China 2024-11-29 22:00
Minghui Pharmaceutical Announces Positive Topline Results from Phase Ⅲ Trial of MH004 (Tofacitinib Etocomil) Ointment in Mild to Moderate Atopic Dermatitis 2024-11-29 20:31
Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference 2024-11-29 10:23
Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline 2024-11-28 21:30
First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients 2024-11-28 17:22
New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List 2024-11-28 16:59
Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List 2024-11-28 13:43
Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country 2024-11-28 13:04
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List 2024-11-28 12:07
Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab 2024-11-28 11:58
Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy 2024-11-27 19:08
Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC 2024-11-27 14:34
111, Inc. Announces Third Quarter 2024 Unaudited Financial Results 2024-11-27 14:00
VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation 2024-11-26 22:00
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology 2024-11-26 18:49
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC) 2024-11-26 17:16
GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment 2024-11-26 08:44
1 5 6 7 8 9 420